Scalper1 News
Big pharma AbbVie (ABBV) beat analysts’ Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today. AbbVie made 82 cents a share in the quarter, the same as the year-earlier quarter but 6 cents above analysts’ consensus. Sales rose 5% to $4.93 billion, topping analysts’ $4.7 billion. The company Scalper1 News
Scalper1 News